PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
15.13%
Positive revenue growth while AVGO is negative. John Neff might see a notable competitive edge here.
13.22%
Positive gross profit growth while AVGO is negative. John Neff would see a clear operational edge over the competitor.
24.19%
EBIT growth 75-90% of AVGO's 27.36%. Bill Ackman would push for cost reforms or better product mix to narrow the gap.
24.19%
Operating income growth at 75-90% of AVGO's 27.36%. Bill Ackman would demand a plan to enhance operating leverage.
14.99%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
13.64%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
15.00%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.84%
Share reduction more than 1.5x AVGO's 2.68%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
-1.25%
Reduced diluted shares while AVGO is at 5.16%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
1.58%
Maintaining or increasing dividends while AVGO cut them. John Neff might see a strong edge in shareholder returns.
150.00%
OCF growth above 1.5x AVGO's 37.27%. David Dodd would confirm a clear edge in underlying cash generation.
185.53%
FCF growth above 1.5x AVGO's 44.98%. David Dodd would verify if the firm’s strategic investments yield superior returns.
118.59%
10Y revenue/share CAGR under 50% of AVGO's 684.21%. Michael Burry would suspect a lasting competitive disadvantage.
121.41%
5Y revenue/share CAGR under 50% of AVGO's 421.32%. Michael Burry would suspect a significant competitive gap or product weakness.
89.07%
3Y revenue/share CAGR similar to AVGO's 90.38%. Walter Schloss would assume both companies experience comparable short-term cycles.
95.20%
10Y OCF/share CAGR under 50% of AVGO's 1681.41%. Michael Burry would worry about a persistent underperformance in cash creation.
263.88%
Below 50% of AVGO's 607.61%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
584.66%
3Y OCF/share CAGR above 1.5x AVGO's 113.80%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
209.42%
Below 50% of AVGO's 6196.48%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
407.77%
Below 50% of AVGO's 1822.58%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
325.96%
3Y net income/share CAGR 50-75% of AVGO's 562.35%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
142.26%
Below 50% of AVGO's 2050.41%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
39.06%
Below 50% of AVGO's 617.64%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
29.74%
Below 50% of AVGO's 383.91%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
65.59%
Below 50% of AVGO's 374.17%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
24.28%
AR growth well above AVGO's 11.79%. Michael Burry fears inflated revenue or higher default risk in the near future.
4.14%
We show growth while AVGO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-0.09%
Negative asset growth while AVGO invests at 0.72%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-3.41%
We have a declining book value while AVGO shows 7.39%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-6.20%
We’re deleveraging while AVGO stands at 0.03%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
1.22%
R&D growth drastically higher vs. AVGO's 1.19%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
7.03%
SG&A growth well above AVGO's 1.03%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.